Ekaterina Manuilova - Concepedia

Author

Ekaterina Manuilova

Also Known As

E Manuilova, E S Manuilova, E S. Manuilova, E. Manuilova, E. S. Manuilova, E.S. Manuilova, Ekaterina Manuilova, Ekaterina S. Manuilova, Manuilova, Ekaterina, Е. С. Мануилова

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Roche Pharma AG (Germany)University of Gothenburg Sahlgrenska University Hospital Skåne University Hospital Lund University

About

Ekaterina Manuilova is an author at Roche Pharma AG (Germany) specializing in medicine, cell biology, and neurodegenerative diseases.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	189
2	Cell Biology	5	5	112
3	Health Sciences	1	1	79
4	Social Sciences	1	1	11
5	Medical Laboratory Science	1	1	42

Ekaterina Manuilova

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid Tobias Bittner, Henrik Zetterberg, Charlotte E. Teunissen, Alzheimer s & Dementia	2015	366
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease Sebastian Palmqvist, Erik Stomrud, Nicholas Cullen, Alzheimer s & Dementia	2022	159
Comparison of Plasma and Urine Biomarker Performance in Acute Kidney Injury Gunnar Schley, Carmen Köberle, Ekaterina Manuilova, PLoS ONE	2015	94
Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid Valeria Lifke, Gwendlyn Kollmorgen, Ekaterina Manuilova, Clinical Biochemistry	2019	94
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging James D. Doecke, Larry D. Ward, Samantha C. Burnham, Alzheimer s Research & Therapy	2020	79
Clinical performance and robustness evaluation of plasma amyloid‐β<sub>42/40</sub> prescreening Christina Rabe, Tobias Bittner, Alexander Jethwa, Alzheimer s & Dementia Geriatric PsychiatryNeurodegenerative DiseasesAlzheimer's DiseaseTreatment EvaluationPlasma Aβ 42	2022	79
First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays Sébastien Boulo, Julia Kuhlmann, Ulf Andréasson, Alzheimer s & Dementia	2020	61
NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction Leon Holzscheiter, Claus Beck, Sandra Rutz, Clinical Chemistry and Laboratory Medicine (CCLM)	2013	46
Mutagenesis in cultured mammalian cells N.I. Shapiro, A.E. Khalizev, Eugeny V. Luss, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis Cell BiologyMutagenesisCultured Mammalian CellsCell Culture	1972	44
Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS Leslie M. Shaw, Oskar Hansson, Ekaterina Manuilova, Clinical Biochemistry	2019	42

Page 1